This research study is a pilot study, and it is the first time investigators are directly examining the effect of standard androgen receptor antagonists on Prostate-Specific Membrane Antigen (PSMA) expression for participants with recurrent, asymptomatic, metastatic hormone-sensitive prostate cancer (mHSPC). This study will measure PSMA levels using standard PET/CT scans and participants will receive standard-of-care androgen receptor antagonist monotherapy.~The research study procedures include screening for eligibility, study imaging and evaluations, blood collections, and follow up visits.~The names of the treatment interventions involved in this study are:~Androgen receptor antagonist monotherapy.~PSMA PET/CT scan~The U.S. Food and Drug Administration (FDA) has approved apalutamide, darolutamide, and enzalutamide for the treatment of prostate cancer.~It is expected that about 15 people will take part in this research study.~Participation in this research study is expected to last about 4 weeks.~Funding for this research study is provided by a philanthropic gift.
The goal of this research study is to determine whether hormonal therapies used early in the course of prostate cancer could increase the amount of Prostate-Specific Membrane Antigen (PSMA) as detected by PET/CT scans for participants with recurrent prostate cancer. This study will measure PSMA levels using standard PET/CT scans and participants will receive standard-of-care androgen receptor antagonist monotherapy.~The names of the treatment interventions involved in this study are:~Androgen receptor antagonist monotherapy.~PSMA PET/CT scan~It is expected that about 15 people will take part in this research study.~Participation in this research study is expected to last about 4 weeks.